Atea Pharmaceuticals (AVIR) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

AVIR Atea Pharmaceuticals

Watchlist

3.160
0.0000.00%

Trading Nov 21 09:40 ET

266.90MMarket Cap-1526P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Atea Pharmaceuticals Presents Three HCV Poster Presentations at AASLD
TipRanksNov 15 11:05 ET
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024
GlobeNewswireNov 15 11:00 ET
Express News | Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at Aasld’s the Liver Meeting 2024
ReutersNov 15 11:00 ET
Morgan Stanley Maintains Atea Pharmaceuticals(AVIR.US) With Hold Rating, Cuts Target Price to $6.2
Moomoo NewsNov 11 08:37 ET · Ratings
Atea Pharmaceuticals Advances in HCV Treatment Development
TipRanksNov 8 00:25 ET
Atea Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
SECNov 7 22:38 ET · Announcements

Comments

Jaguar8

Nov 15 10:01

NEWS

$Atea Pharmaceuticals (AVIR.US)$
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
Atea Pharmaceuticals (AVIR) presented three posters at AASLD's The Liver Meeting 2024 supporting the combination of bemnifosbuvir and ruzasvir for hepatitis C virus (HCV) treatment.
The Phase 2 lead-in cohort showed a 97% SVR12 success rate with an 8-week treatment course.
Key f...

Jaguar8

May 22 08:56

$Atea Pharmaceuticals (AVIR.US)$
NEWS
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

Jaguar8

Apr 29 06:04

$Atea Pharmaceuticals (AVIR.US)$
NEWS
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
Atea Pharmaceuticals, Inc. announced the Phase 1 data presentation at ESCMID Global 2024, highlighting the favorable safety profile of bemnifosbuvir, an oral nucleotide polymerase inhibitor. The results show no cardiotoxicity in healthy participants, supporting the drug's safety profile. Atea aims to address the unmet need for COVID-19 and HCV trea...